Psilocybin for depression is one of the most promising applications of psychedelic therapy. In particular, psilocybin therapy is being studied as an alternative to antidepressants in the treatment of treatment-resistant depression.
In this Drug Science webinar, Dr Mourad Wahba explains the science behind psilocybin for depression, which is currently in clinical trials at a number of psychedelic research centres around the world.
Dr Wahba provides an overview of psilocybin, the psychedelic experience, and how it should be implemented as a therapy, including both preparation and integration sessions.
He explains the completed and currently active clinical trials investigating psilocybin for depression, treatment-resistant depression, and existential anxiety in cancer patients. We then dive deep into the mechanism of action and safety data that has been gathered so far to give a complete overview of psilocybin.
Dr Mourad Wahba is a registrar in psychiatry and a member of the Medical Psychedelics Working Group. He is currently a clinician in the psilocybin for treatment-resistant depression trial at the Newcastle site.
Drug Science is the leading independent scientific body on drugs in the UK. We rely on donations to provide clear, evidence-based information without political or commercial interference. Drug Science webinars are free, so if you’d like to support us then please consider joining the Drug Science Community.